Efficacy of combined administration of 0.2% brimonidine and 0.5% betaxolol in treatment of primary open angle glaucoma and ocular hypertension.
To observe the efficacy of combined use of brimonidine and betaxolol in treatment of primary open angle glaucoma (POAG) and ocular hypertension. A total of 54 patients (90 eyes) with POAG and ocular hypertension were randomly divided into three groups (receiving betaxolol, brimonidine and combined administration of betaxolol and brimonidine respectively). The administration was given twice daily in all groups (0.5% betaxolol, 0.2% brimonidine and 0.5% betaxolol combined with 0.2% brimonidine). The changes in intraocular pressure (IOP) were observed before, and 2, 4, 6, and 8 weeks after treatment. In addition, the adverse reactions were also recorded post-treatment. The mean IOPs at all the time points after treatment were significantly reduced compared with pre-treatment levels (P < 0.05). Patients receiving brimonidine had a greater reduction in IOP compared with their counterparts in the betaxolol group but the difference was not statistically significant. The IOP decline was significantly higher in the combined therapy group than in the other two groups (P < 0.01). Few cases presented with slight discomfort, such as sensation of foreign bodies, ocular irritation, dizziness, headache, fatigue, and dryness of mouth and nose. No severe adverse reactions were noted following administration. Combined use of brimonidine and betaxolol is an efficacious treatment of reducing IOP without severe side effects.